245 related articles for article (PubMed ID: 15956247)
21. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis.
Weinmann L; Wischhusen J; Demma MJ; Naumann U; Roth P; Dasmahapatra B; Weller M
Cell Death Differ; 2008 Apr; 15(4):718-29. PubMed ID: 18202704
[TBL] [Abstract][Full Text] [Related]
22. Selective induction of apoptosis through the FADD/caspase-8 pathway by a p53 c-terminal peptide in human pre-malignant and malignant cells.
Li Y; Mao Y; Rosal RV; Dinnen RD; Williams AC; Brandt-Rauf PW; Fine RL
Int J Cancer; 2005 May; 115(1):55-64. PubMed ID: 15645452
[TBL] [Abstract][Full Text] [Related]
23. PRIMA-1 synergizes with adriamycin to induce cell death in non-small cell lung cancer cells.
Magrini R; Russo D; Ottaggio L; Fronza G; Inga A; Menichini P
J Cell Biochem; 2008 Aug; 104(6):2363-73. PubMed ID: 18442053
[TBL] [Abstract][Full Text] [Related]
24. Role of p38 and JNK MAPK signaling pathways and tumor suppressor p53 on induction of apoptosis in response to Ad-eIF5A1 in A549 lung cancer cells.
Taylor CA; Zheng Q; Liu Z; Thompson JE
Mol Cancer; 2013 May; 12():35. PubMed ID: 23638878
[TBL] [Abstract][Full Text] [Related]
25. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database.
Bykov VJ; Issaeva N; Selivanova G; Wiman KG
Carcinogenesis; 2002 Dec; 23(12):2011-8. PubMed ID: 12507923
[TBL] [Abstract][Full Text] [Related]
26. Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53.
Ramraj SK; Elayapillai SP; Pelikan RC; Zhao YD; Isingizwe ZR; Kennedy AL; Lightfoot SA; Benbrook DM
Int J Cancer; 2020 Aug; 147(4):1086-1097. PubMed ID: 31845320
[TBL] [Abstract][Full Text] [Related]
27. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.
Bykov VJ; Issaeva N; Shilov A; Hultcrantz M; Pugacheva E; Chumakov P; Bergman J; Wiman KG; Selivanova G
Nat Med; 2002 Mar; 8(3):282-8. PubMed ID: 11875500
[TBL] [Abstract][Full Text] [Related]
28. PRIMA-1 cytotoxicity correlates with nucleolar localization and degradation of mutant p53 in breast cancer cells.
Russo D; Ottaggio L; Penna I; Foggetti G; Fronza G; Inga A; Menichini P
Biochem Biophys Res Commun; 2010 Nov; 402(2):345-50. PubMed ID: 20946886
[TBL] [Abstract][Full Text] [Related]
29. PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53.
Zache N; Lambert JM; Wiman KG; Bykov VJ
Cell Oncol; 2008; 30(5):411-8. PubMed ID: 18791272
[TBL] [Abstract][Full Text] [Related]
30. Antitumor Effects of PRIMA-1 and PRIMA-1
Menichini P; Monti P; Speciale A; Cutrona G; Matis S; Fais F; Taiana E; Neri A; Bomben R; Gentile M; Gattei V; Ferrarini M; Morabito F; Fronza G
Cells; 2021 Jan; 10(1):. PubMed ID: 33430525
[TBL] [Abstract][Full Text] [Related]
31. Mutational status of the p53 gene modulates the basal level of jun N-terminal kinase and its inducibility by ultraviolet irradiation in A1-5 rat fibroblasts.
Ramaswamy NT; Pelling JC
Mol Carcinog; 1999 Aug; 25(4):262-72. PubMed ID: 10449033
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.
Wiman KG
Oncogene; 2010 Jul; 29(30):4245-52. PubMed ID: 20498645
[TBL] [Abstract][Full Text] [Related]
33. p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells.
Rangel LP; Ferretti GDS; Costa CL; Andrade SMMV; Carvalho RS; Costa DCF; Silva JL
J Biol Chem; 2019 Mar; 294(10):3670-3682. PubMed ID: 30602570
[TBL] [Abstract][Full Text] [Related]
34. PRIMA-1(MET)/APR-246 targets mutant forms of p53 family members p63 and p73.
Rökaeus N; Shen J; Eckhardt I; Bykov VJ; Wiman KG; Wilhelm MT
Oncogene; 2010 Dec; 29(49):6442-51. PubMed ID: 20818419
[TBL] [Abstract][Full Text] [Related]
35. Identification of a novel synthetic thiazolidin compound capable of inducing c-Jun NH2-terminal kinase-dependent apoptosis in human colon cancer cells.
Teraishi F; Wu S; Zhang L; Guo W; Davis JJ; Dong F; Fang B
Cancer Res; 2005 Jul; 65(14):6380-7. PubMed ID: 16024641
[TBL] [Abstract][Full Text] [Related]
36. Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) induces apoptosis and cell cycle arrest in A549 cells through p53 accumulation via c-Jun NH2-terminal kinase-mediated phosphorylation at serine 15 in vitro and in vivo.
Hsu YL; Cho CY; Kuo PL; Huang YT; Lin CC
J Pharmacol Exp Ther; 2006 Aug; 318(2):484-94. PubMed ID: 16632641
[TBL] [Abstract][Full Text] [Related]
37. [The role of mitogen-activated protein kinase cascades in inhibition of proliferation in human prostate carcinoma cells by raloxifene: an in vitro experiment].
Zhang YX; Kong CZ
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):271-5. PubMed ID: 18361842
[TBL] [Abstract][Full Text] [Related]
38. PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa.
Saha MN; Jiang H; Yang Y; Reece D; Chang H
Mol Cancer Ther; 2013 Nov; 12(11):2331-41. PubMed ID: 24030633
[TBL] [Abstract][Full Text] [Related]
39. Characterizing the sphingomyelinase pathway triggered by PRIMA-1 derivatives in lung cancer cells with differing p53 status.
Soans E; Evans SC; Cipolla C; Fernandes E
Anticancer Res; 2014 Jul; 34(7):3271-83. PubMed ID: 24982331
[TBL] [Abstract][Full Text] [Related]
40. Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors.
Liang Y; Besch-Williford C; Benakanakere I; Thorpe PE; Hyder SM
Breast Cancer Res Treat; 2011 Jan; 125(2):407-20. PubMed ID: 20349129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
